Histogenics logo
Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway
November 29, 2018 08:30 ET | Histogenics Corporation
WALTHAM, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Histogenics logo
Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
November 01, 2018 16:05 ET | Histogenics Corporation
WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
January 02, 2018 08:30 ET | Cascadian Therapeutics, Inc.
SEATTLE, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it received a product-specific pediatric...